These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 9750521

  • 21. [Application of antiandrogens on prostatic diseases].
    Takahashi S, Hasegawa F, Isurugi K.
    Nihon Rinsho; 1994 Mar; 52(3):809-14. PubMed ID: 7513031
    [Abstract] [Full Text] [Related]

  • 22. Goserelin acetate with or without antiandrogen or estrogen in the treatment of patients with advanced prostate cancer: a multicenter, randomized, controlled trial in Japan. Zoladex Study Group.
    Kotake T, Usami M, Akaza H, Koiso K, Homma Y, Kawabe K, Aso Y, Orikasa S, Shimazaki J, Isaka S, Yoshida O, Hirao Y, Okajima E, Naito S, Kumazawa J, Kanetake H, Saito Y, Ohi Y, Ohashi Y.
    Jpn J Clin Oncol; 1999 Nov; 29(11):562-70. PubMed ID: 10678560
    [Abstract] [Full Text] [Related]

  • 23. [Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].
    Bruchovsky N, Goldenberg SL, Rennie PS, Gleave M.
    Urologe A; 1995 Sep; 34(5):389-92. PubMed ID: 7483155
    [Abstract] [Full Text] [Related]

  • 24. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
    Yamamoto A, Sumiyoshi Y, Miyake N, Yokozeki H, Kanayama H, Kagawa S.
    Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
    [Abstract] [Full Text] [Related]

  • 25. Comparison of an LH-RH analogue (Goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group.
    Tyrrell CJ, Altwein JE, Klippel F, Jurincic-Winkler C, Varenhorst E, Lunglmayr G, Boccardo F, Holdaway IM, Haefliger JM, Jordaan JP.
    Eur Urol; 2000 Feb; 37(2):205-11. PubMed ID: 10705200
    [Abstract] [Full Text] [Related]

  • 26. [Antiandrogen withdrawal syndrome].
    Akimoto S.
    Nihon Rinsho; 1998 Aug; 56(8):2135-9. PubMed ID: 9750522
    [Abstract] [Full Text] [Related]

  • 27. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 28. Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. The Prostate Cancer Study Group.
    Akaza H, Homma Y, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Ohashi Y, Aso Y.
    Jpn J Clin Oncol; 2000 Mar; 30(3):131-6. PubMed ID: 10798540
    [Abstract] [Full Text] [Related]

  • 29. [Usefulness and positioning of MAB therapy for prostate cancer].
    Akaza H, Chodak GW, Hirao Y.
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758
    [Abstract] [Full Text] [Related]

  • 30. [Skin reaction induced by subcutaneous injection of LH-RH analogue].
    Segawa N, Nishida T, Hamada S, Azuma H, Katsuoka Y, Nozaki K, Tsuji M.
    Hinyokika Kiyo; 2007 Oct; 53(10):695-8. PubMed ID: 18018584
    [Abstract] [Full Text] [Related]

  • 31. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S, Akaza H.
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [Abstract] [Full Text] [Related]

  • 32. [Studies on changes in the ratio of free to total PSA after endocrine treatment of prostate carcinoma].
    Sumi S, Umeda H, Yano M, Koga F, Arai K, Imai T, Hosoya Y, Maeda S, Honda M, Suzuki T, Yoshida K.
    Hinyokika Kiyo; 1996 Dec; 42(12):937-41. PubMed ID: 9013228
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Advanced prostatic carcinoma--which hormone therapy when?].
    Studer UE.
    Urologe A; 1995 Sep; 34(5):361-6. PubMed ID: 7483151
    [No Abstract] [Full Text] [Related]

  • 35. [Goserelin acetate depot, LH-RH agonist; its properties and therapeutic effects in prostate cancer].
    Koga H, Naito S.
    Nihon Rinsho; 2000 Jul; 58 Suppl():186-90. PubMed ID: 11022711
    [No Abstract] [Full Text] [Related]

  • 36. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, Isaacs JT.
    Cancer Res; 1999 May 15; 59(10):2395-401. PubMed ID: 10344749
    [Abstract] [Full Text] [Related]

  • 37. Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group.
    Bono AV, DiSilverio F, Robustelli della Cuna G, Benvenuti C, Brausi M, Ferrari P, Gibba A, Galli L.
    Urol Int; 1998 May 15; 60 Suppl 1():18-24. PubMed ID: 9563140
    [Abstract] [Full Text] [Related]

  • 38. Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer.
    Sekido N, Kawai K, Akaza H, Koiso K.
    Jpn J Clin Oncol; 1995 Aug 15; 25(4):164-7. PubMed ID: 7545251
    [Abstract] [Full Text] [Related]

  • 39. Recent developments in endocrine treatment of prostate cancer.
    Vogelzang NJ, Kennealey GT.
    Cancer; 1992 Aug 15; 70(4 Suppl):966-76. PubMed ID: 1386283
    [Abstract] [Full Text] [Related]

  • 40. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.
    Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M, Yamanaka H, Japan Study Group of Prostate Cancer (J-CaP).
    Jpn J Clin Oncol; 2007 Oct 15; 37(10):775-81. PubMed ID: 17965423
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.